

Press release

Maschmeyer increases share holding in Biofrontera AG

Leverkusen, 25 March 2013 - Dr. Carsten Maschmeyer participated in a capital increase of Biofrontera AG last year, purchasing 12.5% of the share capital of Biofrontera. Today he has informed Biofrontera AG that his investment companies have purchased additional shares at the stock market, up to a share holding of 15.1% (2,437,618 shares). We refer to our obligatory press release according to §26 of the German Securities Trading Act.

Dr. Maschmeyer has furthermore informed us that he is even more convinced of an excellent development of Biofrontera's business than last year, and he intends to keep the shares long-term, both those purchased last year and those now, beyond a holding period ending in April 2013 he had agreed to last year. He intends to increase his share holding even further since he is convinced of a positive development.

The board of Biofrontera AG specifies that these assumptions and intents are those of Dr. Maschmeyer, and the company is not allowed to comment them. His actions confirm that Dr. Maschmeyer is a reliable and long-term investor for Biofrontera.

About Biofrontera AG

Biofrontera aims at attending and treating the skin, recognizing the aesthetic needs of a person's visual reflection.

Biofrontera is listed in the regulated market of the Frankfurt stock exchange under the symbol B8F and the ISIN DE0006046113.

www.biofrontera.com

For further information:

Prof. Dr. Hermann Lübbert

+49 (0)214 876 32 0
+49 (0)214 876 32 90
press@biofrontera.com

Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany